[go: up one dir, main page]

PE134999A1 - Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal - Google Patents

Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal

Info

Publication number
PE134999A1
PE134999A1 PE1998001138A PE00113898A PE134999A1 PE 134999 A1 PE134999 A1 PE 134999A1 PE 1998001138 A PE1998001138 A PE 1998001138A PE 00113898 A PE00113898 A PE 00113898A PE 134999 A1 PE134999 A1 PE 134999A1
Authority
PE
Peru
Prior art keywords
neuronal
diseases
aminometil
chromanes
impediment
Prior art date
Application number
PE1998001138A
Other languages
English (en)
Inventor
Ervin Horvath
Reinhard Jork
Thomas Fahrig
Irene Gerlach
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE134999A1 publication Critical patent/PE134999A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)

Abstract

SE REFIERE AL USO DE UN COMPUESTO DE FORMULA I DONDE R1 ES H; R2 ES H, OH, -OCH3, -OCH2CH3, -OCH(CH3)2, -OCH2C(CH3)2-Cl; O R1 Y R2 SON -CH2-C(CH3)(CH3)-O-; R3 ES CICLOPENTILO, CICLOHEXILO, CICLOHEPTILO, CICLOOCTILO U O-BENZOSULFIMIDILO; n ES 1-5. EL COMPUESTO I DISMINUYE LA EXPRESION DE LA PROTEINA ACIDA FIBRILAR GLIAL (PAFG), IMPIDIENDO LA FORMACION DEL TEJIDO CICATRICIAL GLIAL Y PERMITIENDO LA FORMACION Y CRECIMIENTO DE PROLONGACIONES NEURONALES POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS; EL ESTIMULO DE LA REGENERACION NEURONAL Y PARA EL TRATAMIENTO REGENERATIVO DE DANOS POR INTERVENCIONES QUIRURGICAS, INFECCIONES, IMPLANTES, EXPOSICION A AGENTES TOXICOS, TUMORES, DEFICIENCIAS NUTRITIVAS O ENFERMEDADES METABOLICAS, ENFERMEDAD DE PARKINSON, ESCLEROSIS MULTIPLE, ESCLEROSIS LATERAL AMIOTROPICA, EPILEPSIA, ABUSO DE DROGAS, DROGADICCION, ENFERMEDADES O LESIONES DE LA MEDULA ESPINAL, DISTROFIA DE LA RETINA NEURAL
PE1998001138A 1997-11-24 1998-11-23 Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal PE134999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19751949A DE19751949A1 (de) 1997-11-24 1997-11-24 Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration

Publications (1)

Publication Number Publication Date
PE134999A1 true PE134999A1 (es) 2000-03-05

Family

ID=7849618

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001138A PE134999A1 (es) 1997-11-24 1998-11-23 Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal

Country Status (30)

Country Link
US (2) US6235774B1 (es)
EP (1) EP1051170B1 (es)
JP (1) JP2001523716A (es)
KR (1) KR20010032357A (es)
CN (1) CN1134256C (es)
AR (1) AR016973A1 (es)
AT (1) ATE206615T1 (es)
AU (1) AU745759B2 (es)
BG (1) BG64167B1 (es)
CA (1) CA2311126A1 (es)
DE (2) DE19751949A1 (es)
DK (1) DK1051170T3 (es)
ES (1) ES2164465T3 (es)
HN (1) HN1998000169A (es)
HU (1) HUP0004369A3 (es)
IL (1) IL135904A (es)
IS (1) IS5496A (es)
MY (1) MY118414A (es)
NO (1) NO20002638L (es)
NZ (1) NZ504656A (es)
PE (1) PE134999A1 (es)
PL (1) PL340674A1 (es)
PT (1) PT1051170E (es)
RU (1) RU2217140C2 (es)
SI (1) SI1051170T1 (es)
SV (1) SV1998000138A (es)
TR (1) TR200001471T2 (es)
TW (1) TW524690B (es)
WO (1) WO1999026621A1 (es)
ZA (1) ZA9810668B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
CA2400637A1 (en) * 2000-03-17 2001-09-27 Robert J. Collier, Jr. Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
DE10058119A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
SE0004455D0 (sv) * 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
DE10101917A1 (de) * 2001-01-16 2002-07-18 Bayer Ag Verwendung von Chromanen
BR0211358A (pt) * 2001-07-26 2004-09-21 Merck Patent Gmbh Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
KR100886185B1 (ko) * 2001-09-12 2009-02-27 메르크 파텐트 게엠베하 운동 장애의 치료 및 추체외로 운동 장애의 치료를 위해 투여된 약물에 의해 유도된 부작용의 치료를 위한 치환된 아미노메틸 크로만의 신규한 용도
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
DE102004017627A1 (de) * 2004-04-10 2005-10-27 Bayer Healthcare Ag Verwendung von vollen 5-HT1A-Agonisten zur Hemmung der opiat/opioid-induzierten Atemdepression
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
CN116283877A (zh) 2016-07-29 2023-06-23 赛诺维信制药公司 化合物、组合物及其用途
RU2651756C1 (ru) * 2017-05-10 2018-04-23 Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ Препарат для предотвращения образования глиальных рубцов
KR20200036008A (ko) * 2017-08-02 2020-04-06 선오비온 파마슈티컬스 인코포레이티드 이소크로만 화합물 및 이의 용도
CA3130849A1 (en) 2019-03-14 2020-09-17 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300523A (en) 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
DE19522088A1 (de) 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration

Also Published As

Publication number Publication date
TW524690B (en) 2003-03-21
TR200001471T2 (tr) 2000-10-23
HUP0004369A2 (hu) 2001-04-28
PL340674A1 (en) 2001-02-12
US20010018530A1 (en) 2001-08-30
ZA9810668B (en) 1999-05-26
SV1998000138A (es) 1999-05-25
HN1998000169A (es) 1999-11-03
KR20010032357A (ko) 2001-04-16
IS5496A (is) 2000-05-15
NO20002638D0 (no) 2000-05-23
DE19751949A1 (de) 1999-05-27
WO1999026621A1 (de) 1999-06-03
AU745759B2 (en) 2002-03-28
US6235774B1 (en) 2001-05-22
JP2001523716A (ja) 2001-11-27
HUP0004369A3 (en) 2002-04-29
NO20002638L (no) 2000-05-23
AR016973A1 (es) 2001-08-01
BG104466A (en) 2001-02-28
US6331561B2 (en) 2001-12-18
CN1279604A (zh) 2001-01-10
ES2164465T3 (es) 2002-02-16
DK1051170T3 (da) 2001-12-27
CA2311126A1 (en) 1999-06-03
IL135904A0 (en) 2001-05-20
PT1051170E (pt) 2002-02-28
IL135904A (en) 2003-07-06
SI1051170T1 (en) 2001-12-31
BG64167B1 (bg) 2004-03-31
RU2217140C2 (ru) 2003-11-27
NZ504656A (en) 2002-02-01
ATE206615T1 (de) 2001-10-15
CN1134256C (zh) 2004-01-14
AU1668599A (en) 1999-06-15
EP1051170B1 (de) 2001-10-10
MY118414A (en) 2004-10-30
DE59801724D1 (de) 2001-11-15
EP1051170A1 (de) 2000-11-15

Similar Documents

Publication Publication Date Title
PE134999A1 (es) Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal
ES2399738T3 (es) Procedimiento y composición para el tratamiento de cicatrices
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
BR0010869A (pt) Método para administrar um corticosteróide a um segmento posterior de um olho e dispositivo de liberação sustentada implantável
ES2141706T3 (es) Formulaciones y su empleo en el tratamiento de enfermedades neurologicas.
BR9808938A (pt) Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
BRPI0820800B8 (pt) dispositivo médico implantável para liberação controlada de droga
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
BR9809453A (pt) Composição de suprimento de medicamento para a liberação controlada de um ingrediente ativo dentro do meio-ambiente do estÈmago, uso da mesma, formulação farmacêutica, processo para obter gastrorretenção, para o tratamento ou profilaxia de uma doença, para melhorar a absorção gastrointestinal de medicamentos, e para a preparação de uma composição, e, estojo de partes para uso no tratamento de infecção por h. pylori.
DE69715049D1 (de) Tranilast enthaltendes externum und verfahren zu dessen herstellung
SI9111227B (sl) Farmacevtski preprat z aktivno materijo Flupirtin za zdravljenje bolezni, ki se nanašajo na napetost mišic
BR0107983A (pt) Uso de pramipexol para o tratamento de enfermidades decorrentes de vìcios
BR0311558A (pt) composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica
BR0210034A (pt) Conjunto de partes, método para tratamento de trombose, uso de um composto, formulação farmacêutica, uso e processo para preparação da mesma, e, composto
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
DE69602412D1 (de) Ophthalmische Zubereitung zur Behandlung oder Prävention von trockenem Auge und Krankheiten, die dadurch verursacht werden, enthaltend 12-Sulfodehydroabietsäure
BR9807796A (pt) Processos para tratar da incontinência urinária, de vertigem e da doença do movimento, e, composição farmacêutica.
DE50110262D1 (de) Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen
BR0316040A (pt) Composto, métodos para tratar doenças, para tratar edema macular, degeneração macular, aumentar a velocidade do sangue retinal e da cabeça do nervo óptico, aumentar a tensão de oxigênio retinal e do nervo óptico e/ou um efeito neuroprotetor, para prevenir a repolarização ou a hiperpolarização de uma célula de mamìfero contendo canal de potássio, e para tratar do diabete, e, composição
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
MXPA02009881A (es) Nuevos medicamentos intracorporales para tratamiento fototerapeutico con alta energia de enfermedad.
DE60130030D1 (de) Verfahren zur behandlung von glaukom
PT99864A (pt) Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica

Legal Events

Date Code Title Description
FC Refusal